Medication info
Hymet Tablet 15/850 mg

Hymet Tablet 15/850 mg

Prescription medicationTablet
Ingredient · strength
Metformin Hydrochloride›850mg / 1 tabletPioglitazone Hydrochloride›16.53mg / 1 tablet
Manufacturer / importer
White Life Science Co., Ltd.
Appearance
White to grayish-white rectangular film-coated tablet
Packaging
30 tablets/PTP[(10 tablets/PTP*3)]
Approval status
Active

MFDS item code 202000339 · Approved 2020.01.21 · Insurance code 625201970

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum dose of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with pioglitazone or metformin monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this medicine daily and gradually adjust the dose after evaluating the adequacy of the treatment response. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this medicine may start at the doses of pioglitazone and metformin they were previously receiving. No studies have been conducted to evaluate the safety and efficacy of switching from another oral glucose-lowering medicine to this medicine. Any change in the treatment regimen for type 2 diabetes may lead to changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on a careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not have their dose increased to the maximum dose of this medicine. After administering this medicine to a patient or increasing the dose, monitor carefully for adverse reactions associated with fluid retention. This medicine should generally be administered in divided doses with meals, which can reduce gastrointestinal adverse reactions caused by metformin. Sufficient time is needed to evaluate the adequacy of the treatment response. Ideally, the response to treatment should be evaluated using glycated hemoglobin (HbA1C), which is a better indicator of long-term blood glucose control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the past 2 - 3 months. In clinical use of this medicine, if blood glucose control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) is recommended to assess changes in HbA1C.

Ingredients

Manufacturer
White Life Science Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to help control blood sugar in patients with type 2 diabetes while implementing dietary and exercise therapy. The combination of pioglitazone and metformin effectively lowers blood sugar levels, aiding in the management of diabetes. Therefore, this medication is used to improve blood sugar and treat diabetes.

Dosage and Administration

Adult dosage

For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum dose of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with pioglitazone or metformin monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this medicine daily and gradually adjust the dose after evaluating the adequacy of the treatment response. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this medicine may start at the doses of pioglitazone and metformin they were previously receiving. No studies have been conducted to evaluate the safety and efficacy of switching from another oral glucose-lowering medicine to this medicine. Any change in the treatment regimen for type 2 diabetes may lead to changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on a careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not have their dose increased to the maximum dose of this medicine. After administering this medicine to a patient or increasing the dose, monitor carefully for adverse reactions associated with fluid retention. This medicine should generally be administered in divided doses with meals, which can reduce gastrointestinal adverse reactions caused by metformin. Sufficient time is needed to evaluate the adequacy of the treatment response. Ideally, the response to treatment should be evaluated using glycated hemoglobin (HbA1C), which is a better indicator of long-term blood glucose control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the past 2 - 3 months. In clinical use of this medicine, if blood glucose control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) is recommended to assess changes in HbA1C.

Precautions

This medication can cause severe lactic acidosis and hypoglycemia, so caution is needed especially in patients with impaired kidney function or heart disease. Lactic acidosis is a rare but very serious condition that can occur due to the accumulation of metformin in the body, and it can be fatal. This medication should not be administered to patients with liver dysfunction, dehydration, sepsis, or hypoxia, and if these conditions occur, medication should be stopped immediately. Patients with heart failure, especially those with severe heart failure, should not use this medication, and if symptoms of heart failure occur, they should consult a doctor immediately. Patients with active bladder cancer or a history of bladder cancer should carefully consider the risks and benefits before administering this medication. It should not be given to pregnant or breastfeeding women, and safety has not been established in pediatric patients. Elderly patients may have decreased kidney function, so dosage adjustment and kidney function testing are necessary. This medication may interact with other drugs; therefore, it is essential to inform the doctor or pharmacist of any other medications being taken. While taking this medication, regular blood sugar tests and evaluations of liver and kidney functions should be conducted to monitor health conditions periodically. In case of overdose, it is essential to visit a medical institution immediately for appropriate treatment, as metformin can be removed from the blood by dialysis. Alcohol can increase the risk of side effects from this medication, so excessive drinking should be avoided while taking this medication. During the course of taking this medication, consistent adherence to dietary and exercise therapy is necessary, and if symptoms of hypoglycemia or lactic acidosis occur, immediate consultation with medical personnel is required.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • lethargy
  • myalgia
  • dyspnea
  • asthenia
  • abdominal pain
  • hypothermia
  • hypotension
  • resistant bradyarrhythmia
Show 37 more
  • upper respiratory tract infection
  • diarrhea
  • complex edema
  • peripheral edema
  • headache
  • nausea
  • urinary tract infection
  • sinusitis
  • dizziness
  • lower extremity edema
  • weight gain
  • myalgia
  • dental disorders
  • worsening of diabetes
  • pharyngitis
  • anemia
  • vision loss
  • diabetic macular edema
  • liver failure
  • congestive heart failure
  • edema
  • weight gain
  • dyspepsia
  • insomnia
  • dry mouth
  • constipation
  • abdominal distension
  • abnormal blood glucose
  • arthralgia
  • increased serum creatinine
  • increased blood urea nitrogen
  • fractures
  • elevated serum transaminase levels
  • increased creatine phosphokinase levels
  • gross hematuria
  • urinary disorders
  • urgency

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to protect it from air and moisture. It is advisable to maintain a storage temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

White to grayish-white rectangular film-coated tablet

Package unit

30 tablets/PTP[(10 tablets/PTP*3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.